Literature DB >> 10430096

Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu.

R L Hong1, W H Spohn, M C Hung.   

Abstract

Curcumin, a natural compound present in turmeric, possessing both anti-inflammatory and antioxidant effects, has been studied vigorously as a chemopreventative in several cancer models. The erbB2/neu gene-encoded p185neu tyrosine kinase is a potent oncoprotein. Overexpression of p185neu in breast cancer is known to be a poor prognostic factor. We investigated the effect of curcumin on p185neu tyrosine kinase and on the growth of breast cancer cell lines. Curcumin dose-dependently inhibited p185neu autophosphorylation and transphosphorylation in vitro and depleted p185neu protein in vivo. It dissociated the binding of p185neu with GRP94 (glucose-regulated protein), a molecular chaperone, and enhanced the depletion of p185neu. The amount of p185neu protein on the cell membrane was drastically decreased after curcumin treatment. These data demonstrated a new mechanism of the anti-tyrosine kinase activity of curcumin. The growth of several breast cancer cell lines was inhibited; the IC50 ranged from 7 to 18 microM, which, however, did not correlate with the expression level of p185neu. Colony formation in the soft agar assay, a hallmark of the transformation phenotype, was preferentially suppressed in p185neu-overexpressing cell lines by 5 microM curcumin (% of control, basal level versus overexpression: 59.3 versus 16.7%; P < 0.001 by Student's t test). Because curcumin effectively inhibited p185neu tyrosine kinase activity by depleting p185neu and potently suppressed the growth of multiple breast cancer cell lines, its therapeutic potential in advanced breast cancer is worthy of further investigation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10430096

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  36 in total

Review 1.  Cancer cell signaling pathways targeted by spice-derived nutraceuticals.

Authors:  Bokyung Sung; Sahdeo Prasad; Vivek R Yadav; Bharat B Aggarwal
Journal:  Nutr Cancer       Date:  2011-12-09       Impact factor: 2.900

2.  Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus.

Authors:  Mads Lerdrup; Silas Bruun; Michael V Grandal; Kirstine Roepstorff; Malene M Kristensen; Anette M Hommelgaard; Bo van Deurs
Journal:  Mol Biol Cell       Date:  2007-07-11       Impact factor: 4.138

3.  Chloroquine supplementation increases the cytotoxic effect of curcumin against Her2/neu overexpressing breast cancer cells in vitro and in vivo in nude mice while counteracts it in immune competent mice.

Authors:  L Masuelli; M Granato; M Benvenuto; R Mattera; R Bernardini; M Mattei; G d'Amati; G D'Orazi; A Faggioni; R Bei; M Cirone
Journal:  Oncoimmunology       Date:  2017-07-31       Impact factor: 8.110

4.  Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin.

Authors:  Peter Tsvetkov; Gad Asher; Veronica Reiss; Yosef Shaul; Leo Sachs; Joseph Lotem
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-04       Impact factor: 11.205

5.  Curcumin inhibits protein phosphatases 2A and 5, leading to activation of mitogen-activated protein kinases and death in tumor cells.

Authors:  Xiuzhen Han; Baoshan Xu; Christopher S Beevers; Yoshinobu Odaka; Long Chen; Lei Liu; Yan Luo; Hongyu Zhou; Wenxing Chen; Tao Shen; Shile Huang
Journal:  Carcinogenesis       Date:  2012-01-31       Impact factor: 4.944

6.  Ganoderic acid targeting multiple receptors in cancer: in silico and in vitro study.

Authors:  Balraj Singh Gill; Sanjeev Kumar
Journal:  Tumour Biol       Date:  2016-09-03

7.  Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf.

Authors:  Basem S Goueli; Ralf Janknecht
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

8.  Mechanisms for the activity of heterocyclic cyclohexanone curcumin derivatives in estrogen receptor negative human breast cancer cell lines.

Authors:  Tiffany J Somers-Edgar; Sebastien Taurin; Lesley Larsen; Anupama Chandramouli; Mark A Nelson; Rhonda J Rosengren
Journal:  Invest New Drugs       Date:  2009-10-09       Impact factor: 3.850

9.  Fabrication and characterization of silk fibroin-derived curcumin nanoparticles for cancer therapy.

Authors:  Vishal Gupta; Abraham Aseh; Carmen N Ríos; Bharat B Aggarwal; Anshu B Mathur
Journal:  Int J Nanomedicine       Date:  2009-04-20

10.  Modulation of the BRCA1 Protein and Induction of Apoptosis in Triple Negative Breast Cancer Cell Lines by the Polyphenolic Compound Curcumin.

Authors:  Danica L Rowe; Tuba Ozbay; Ruth M O'Regan; Rita Nahta
Journal:  Breast Cancer (Auckl)       Date:  2009-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.